Sana Biotechnology, Inc. (SANA) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped SANA stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: Sana Biotechnology shows strong potential given its field-leading innovations in regenerative medicine, despite risks like regulatory challenges and high operating expenses. Its robust pipeline and positive early stage trial results suggest it could outpace traditional market returns, making it a compelling candidate for long-term growth investment. The saved 1-year distribution is P10 $2.5, P50 $4.5, and P90 $7.5.
Last analyzed · Model: gpt-4o
Sana Biotechnology, Inc. Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $2.5 | Pessimistic plausible scenario |
| P50 | $4.5 | Median scenario |
| P90 | $7.5 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
Sana Biotechnology has robust pipeline development, investor interest, and recent positive trial data, although FDA hurdles introduce risk.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this SANA analysis generated?
March 9, 2026.
Is this a guaranteed SANA prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full SANA stock analysis · SANA sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.